c4therapeutics.com (CCCC) - יתרות מזומנים למניה אחת

סמל תאגידי ולוגו של C4 Therapeutics Corp (CCCC)

Toxicity risks of early-stage drugs are constraining growth, although partner advances are mitigating liquidity deficits. An analysis of cash per share clearly confirms solvency, where 1.55 serves as the final level marker. The team is effectively protecting patents and raising capital, while the strong scientific reputation of C4 Therapeutics, Inc. (CCCC) in targeted therapy strengthens physician confidence in cancer treatment methods.

c4therapeutics.com (CCCC) - מזומנים למניה אחת מ-04.07.2022 עד 20.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור C4 Therapeutics Corp (CCCC)

- מחיר שוק ויעדי מחיר של אנליסטים:
- פרטי פוזיציית מזומנים ותזרימי מזומנים:
ניתוח מקיף של החברה:C4 Tx - CCCC
סחורת הדגל של C4 Tx

For C4 Therapeutics, Inc. (CCCC), which is developing a protein degradation platform in oncology, maintaining sufficient capital to fund clinical phases and expansion is critical. This metric is calculated as the ratio of total liquid assets to the number of shares, determining the actual cash support for each security and the level of financial stability. By analyzing the trend of liquid assets per share, an investor can assess the risk of asset undervaluation or the presence of excess idle capital.